Bovine luteal cyclic AMP and cyclic GMP phosphodiesterase activity; sensitivity to various drugs and hormones  by Goff, A.K. & Major, Patricia W.
Volume 6 1, number 2 FEBS LETTERS January 1976 
BOVINE LUTEAL CYCLIC AMP AND CYCLIC GMP PHOSPHODIESTERASE ACTIVITY; 
SENSITIVITY TO VARIOUS DRUGS AND HORMONES 
A. K. GOFF and Patricia W. MAJOR 
Section of Pharmacology, Academic Division of Medicine, The University of Sheffield, Sheffield, SI 0 2TN, England 
Received 10 November 1975 
1. Introduction 
Previous studies have shown the presence of two 
forms of cyclic AMP phosphodiesterase activity in 
bovine corpus luteum tissue [l] . These enzymes have 
K, values of approx. 2 X 1 O4 M and 1 X 1 Oe6 M, 
similar to those of other tissues studied [2]. However 
to our knowledge the presence of cyclic GMP phos- 
phodiesterase activity has not been demonstrated in 
ovarian tissue. This study indicates that a cyclic GMP 
phosphodiesterase is present in bovine luteal tissue. 
The effects of known inhibitors of phosphodi- 
esterase activity were studied to establish whether 
they had selective effects in inhibiting either the 
cyclic AMP or cyclic GMP phosphodiesterase from 
ovarian tissue. It has been previously reported that 
many inhibitors of phosphodiesterase are more 
effective in preventing cleavage of cyclic AMP than 
cyclic GMP [2] , although this varies from tissue to 
tissue [3] . 
The effects of various drugs and hormones were 
determined with a view to finding doses at which 
different effects might be dissociated. Of special 
interest were the effect of indomethacin, which is a 
potent inhibitor of prostaglandin biosynthesis [4] 
and flufenamic acid which antagonises the effect of 
prostaglandin Fza [S] since these compounds have 
been reported to also have the ability to inhibit 
phosphodiesterase activity in other tissues [6,7]. 
2. Materials and methods 
2.1. Chemicals 
Cyclic AMP, cyclic GMP, snake venom (Crotalus 
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atrox), indomethacin, histamine, 17P-estradiol, 
progesterone, 20a-hydroxy-4-pregnen-3-one were 
purchased from Sigma Chemical Company; anion 
exchange resin (AGl-X2 400 mesh) was supplied by 
Bio-Rad; RO 07-2956 and RO 20-l 724 were given 
by Roche; ICI 63, 197 was supplied by I.C.I.; nuper- 
Caine was obtained from Ciba; ascorbic acid was 
obtained from Eastman Organic Chemicals; flufenamic 
acid (ARLEF) was supplied by Parke-Davis and 
prostaglandins Fza and Ez were supplied by the 
Upjohn Company. Adenosine [S-3H] 3’ 5’ cyclic 
phosphate ammonium salt (spec. act. 20.7 Ci/mmol) 
and guanosine [8-3H] 3’ 5’ cyclic phosphate ammo- 
nium salt (spec. act. 13 Ci/mmol) came from the 
Radiochemical Centre, Amersham. Other chemicals 
were supplied by British Drug Houses. 
2.2. Enzyme prepration 
A crude enzyme preparation was made by homo- 
genizing approx. 1 g of corpus luteum tissue in 12 ml 
Tris/Mg” buffer, pH 8 (8 ml 0.05 M Tris, pH 8 and 
4 ml 10 mM MgC12). The homogenate was centrifuged 
at 5000 g for 30 min at 4°C and the supernatant 
fraction was dispensed into 0.5 ml aliquots and stored 
at -2O’C until required. 
No separation or purification of the different 
isoenzymes was undertaken, however the low concen- 
tration used should reflect the activity of the low 
KM enzyme, which is thought to be of the greatest 
physiological importance. 
2.3. Determination of cyclic AMP and cyclic GMP 
phosphodiesterase activities 
A modification of the radiodisplacement assay of 
Brooker, Thomas and Appleman [8] was used. The 
North-Holland Publishing Company - Amsterdam 
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reaction mixture contained 70 mM Tris-HCl buffer, 
pH 8,40 mM magnesium chloride; 0.8 mM EDTA; 
0.05 /Ki [3H] cyclic AMP or cyclic GMP; unlabelled 
cyclic AMP or cyclic GMP at various concentrations 
and enzymatic preparation containing 1 mg/ml snake 
venom. All the assays were carried out in linearity 
conditions with respect to time and protein concen- 
tration, allowing measurement of the initial rates of 
reaction. Protein concentrations were determined by 
the method of Lowry et al. [9] using bovine serum 
albumin as standard. 
3. Results 
Kinetic analysis of both cyclic AMP and cyclic 
GMP phosphodiesterase activity using Lineweaver- 
Burke plots (fig. 1.) shows that both phosphodiesterases 
have similar values for the KM. Over the range of 
3.3. X lo-’ M to 5 X low6 M an apparent KM of 
2.80 + 0.31 X 10e6 M and a Vmax of 5.18 rt 0.32 
pmol/ 10 min/pg protein was obtained for cyclic AMP, 
and an apparent KM of 4.09 + 0.72 X 1Qe6 M and a 
V max of 8.89 + 0.83 pmol/lO min/pg protein was 
obtained for cyclic GMP phosphodiesterase. 
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The effects of various known inhibitors of phos- 
phodiesterase activity on ovarian cyclic AMP and 
cyclic GMP phosphodiesterase activities are shown in 
table 1. Both the Roche compounds (RO 07-2956 
and RO 20-l 724) and ICI 63, 197 appear to be more 
specific for the cyclic AMP phosphodiesterase than 
the cyclic GMP phosphodiesterase. However theo- 
phylline and papaverine were able to inhibit both the 
Table 1 
Effect of some inhibitors of phosphodiesterase activity on 
bovine luteal cyclic AMP and cyclic GMP phosphodiesterase 
activity at low substrate concentrations 
I,, OcM) 
Cyclic AMP phosphodiesterase Cyclic GMP 
phosphodiesterase 
RO 20-1724 8.2 1800 
RO 07-29.56 130 3300 
ICI 63,197 10 580 
Theophylhne 750 360 
Papaverine 5.8 7.2 
I,, represents the concentration of drug required to cause a 
50% inhibition of enzyme activity. Cyclic nucleotide sub- 
strate concentration of 5 X lo-’ M was used in the assays. 
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Fig.1. Lineweaver-Burke plots of, (A) bovine luteal cyclic AMP phosphodiesterase assayed over the range 5 X 10e6 M-3.3 X IO-’ 
M. (0) Controls; (0) effect of 1 X lo-’ M indomethacin; (u) effect of 3 X lo-’ M papaverhte; (4) effect of 1.3 X lo-’ M theo- 
phylline. (B) Bovine luteal cyclic GMP phosphodiesterase assayed over the range 5 X 1Om6 M-3.3 X lo-’ M. (0) Controls; (A) 
effect of 3.3 X lo-’ M theophylline; (m) effect of 3 X low6 M papaverine; (0) effect of 2 X 10e5 M indomethacin. Each point is 
the mean of four determinations, bars represent S.E.M. Y = pmoles cyclic nucleotide hydrolyzed/lo min/pg protein. 
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Table 2 
Effect of various drugs and hormones on bovine luteal cyclic AMP and cyclic GMP 
phosphodiesterase activities at low substrate concentrations 
Indomethacin 
Flufenamic acid 
Nupercaine 
Human chorionic 
gonadotrophin (HCG) 
CaCl, 
Histamine 
Prostaglandin E, 
Prostaglandin F, d 
17p-estradiol 
Progesterone 
20a-hydroxy-4-pregnen-3-one 
Ascorbic acid 
Cyclic AMP 
Cyclic GMP 
Cyclic AMP 
phosphodiesterase 
500 
280 
800 
No effect 
No effect 
No effect 
No effect 
No effect 
2000 
90 
5500 
No effect 
_ 
1300 
Cyclic GMP 
phosphodiesterase 
100 
400 
500 
No effect 
No effect 
No effect 
No effect 
No effect 
800 
160 
6500 
No effect 
2500 
_ 
I,, represents the concentration of drug required to cause a 50% inhibition of enzyme 
activity. Cyclic nucleotide substrate concentration of 5 X lo-’ M was used in the 
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assays. 
cyclic AMP and cyclic GMP phosphodiesterases to the 
same extent; papaverine being the most potent sub- 
stance tested. 
The effects of the other drugs and hormones on 
phosphodiesterase activity are shown in table 2. All 
three antagonists of prostaglandin synthesis or action 
(indomethacin; flufenamic acid and nupercaine) were 
found to be fairly potent inhibitors of phosphodi- 
esterase activity, having IsOs comparable with theo- 
phylline. Indomethacin had a similar Iso in corpus 
luteum tissue to that found in human synoviocytes 
[7]. The results of Ferre et al. [6] also show that 
indomethacin and flufenamic acid are of equal 
potency in inhibiting cyclic AMP phosphodiesterase 
from human placenta. HCG, calcium chloride, 
histamine, prostaglandins Ez, Fzcu and ascorbic acid 
at concentrations ranging from lo- M - 10m3 M had 
no detectable effect on the phosphodiesterase activity. 
However the three steroid hormones tested were able 
to inhibit phosphodiesterase activity, the most potent 
of these was progesterone. This is in agreement with 
the results of Ferre et al. [6] who found that proge- 
sterone had a strong inhibitory action whereas fi- 
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estradiol was less effective. Cyclic AMP was able to 
inhibit cyclic GMP phosphodiesterase and cyclic GMP 
was able to inhibit cyclic AMP phosphodiesterase, but 
only at relatively high concentrations. 
The type of inhibition exhibited by some of the 
drugs used was also investigated. Fig. 1 shows the 
effect of theophylline, papaverine and indomethacin 
on Lineweaver-Burke plots for cyclic AMP and 
cyclic GMP phosphodiesterase activity. Theophylline 
and indomeihacin appear to exhibit a non-competi- 
tive type of inhibition for both cyclic nucleotide 
phosphodiesterases, whereas papaverine exhibited a 
competitive type for cyclic GMP phosphodiesterase 
but a mixed type for cyclic AMP phosphodiesterase. 
The type of inhibition exhibited by the two Roche 
compounds and ICI 63,197 were also investigated. 
For cyclic AMP phosphodiesterase, RO 20- 1724 
inhibited non-competitively whereas RO 07-2956 
and ICI 63, 197 inhibited competitively. For cyclic 
GMP phosphodiesterase, RO 20-1724 inhibited 
competitively whereas the ICI 63, 197 and RO 07- 
2956 exhibited a mixed type of inhibition. 
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4. Discussion 
This study has shown that bovine corpus luteum 
tissue contains soluble phosphodiesterases which are 
able to hydrolyse both cyclic AMP and cyclic GMP. 
These phosphodiesterases have similar K, values at 
the low substrate concentrations used. The cyclic 
AMP phosphodiesterase appears to be distinct from 
the cyclic GMP phosphodiesterase. There are two 
reasons for this; (a) the activity of the two cyclic 
nucleotide phosphodiesterases are affected differently 
by some of the drugs tested. For example, RO 20- 
1724 at a concentration of only 8 PM was necessary 
to cause a 50% inhibition of cyclic AMP phosphodi- 
esterase, whereas a concentration of 1800 /IM was 
necessary to cause a 50% inhibition of cyclic GMP 
phosphodiesterase; (b) cyclic AMP only inhibits 
cyclic GMP phosphodiesterase activity at relatively 
high concentrations (Is0 = 2 mM) and vice versa. If 
the same enzyme was hydrolysing both cyclic nucleo- 
tides then a lower I50 would be expected. 
It has been found that in various tissues each of 
these cyclic nucleotides is able to influence the rate 
of hydrolysis of the other [lo] either stimulating or 
inhibiting the rate of hydrolysis of the other depend- 
ing on its concentration. However we found no 
ability of either cyclic nucleotide to stimulate the 
rate of hydrolysis of the other. On the other hand 
both cyclic nucleotides were able to inhibit the hydro- 
lysis of the other, but the Iso is far greater than the 
physiological concentration, so it is doubtful whether 
this has any physiological significance. 
An interesting observation was the fact that 
progesterone, 20ol-hydroxy-4-pregnen-3-one and 17/3- 
estradiol were able to inhibit both cyclic AMP and 
cyclic GMP phosphodiesterases. Similar observations 
have been noted in human placental tissue [6] and it 
seems likely that this phenomenon has a physiological 
significance. There was a surprising difference between 
the Is0 for progesterone and the Iso for 20&hydroxy- 
4-pregnen-3-one, since there is only a slight difference 
in the chemical structure of these two steroids. 
Calcium ions, in low concentrations, stimulate 
phosphodiesterase activity in rat brain in the presence 
of Mg’+ but such a stimulation was not found in 
other rat tissues [ 1 l] . In rat pancreas [ 121 Ca2+ 
does not stimulate phosphodiesterase but has an 
inhibitory effect when added in concentrations above 
0.1 mM. In bovine corpus luteum tissue, calcium 
appears to have no effect at all on phosphodiesterase 
activity. 
Acknowledgement 
This work was supported by a grant from the 
Medical Research Council. 
References 
[ 11 Michie, J., Leakey, J. and Stansfield, D. A. (1974) 
Biochemical Society Transactions 2,438-440. 
[2] Appleman, M. M., Thompson, W. J. and Russell, T. R. 
(1973) in: Advances in Cyclic Nucleotide Research Vol 
3, pp. 65-98. (P. Greengard and G. A. Robison, eds.) 
New York, Raven Press. 
[ 3) Amer, M. S. and Kreighbaum, W. E. (1975) J. Pharma- 
ceutical Sciences 64, l-36. 
[4] Vane, J. R. (1971) Nature, New Biology, 231, 232. 
[5] Collier, H. C. J. and Sweatman, W. J. F. (1968) Nature 
219,864-865. 
[6] Ferre, F., Breuiller, M. and Cedard, L. (1975) FEBS 
Lett. 52, 295-299. 
[7] Ciosek, C. P., Ortel, R. W., Thannassi, N. M. and 
Newcombe, D. S. (1974) Nature 251, 148-150. 
(81 Brooker, G., Thomas, L. J. and Appleman, M. M. (1968) 
Biochemistry 7,4177-4181. 
[9] Lowry, 0. H., Rosebrough, N. J., Farr, A. L. and 
Randall, R. J. (1951) J. Biol. Chem. 193,‘265-275. 
[lo] Beavo, J. A., Hardman, J. G. and Sutherland, E. W. 
(1970) J. Biol. Chem. 245,5649-5655. 
[ 1 l] Miki, N. and Yoshida, H. (1972) Biochim. Biophys. 
Acta 268, 166-174. 
[12] Rutten, W. J., Schoot, B. M., De Pont, J. J. and Bonting, 
S. L. (1973) Biochim. Biophys. Acta 315, 384-393. 
147 
